What Is Poliomyelitis? The Virus That Once Terrorized America

What Is Poliomyelitis and Why Did It Once Paralyze Thousands?

Poliomyelitis is an enterovirus infection that peaked in the United States in 1952 with more than 21,000 paralytic cases. This RNA virus has three distinct serotypes and spreads through the fecal-oral route, causing paralysis in roughly 1% of infections by destroying motor neurons in the spinal cord and brainstem.

Dr. Kumar’s Take

The CDC data shows polio’s devastating impact before vaccines - over 21,000 paralytic cases in a single year. What’s remarkable is that most infections were actually mild or asymptomatic, making the paralytic cases even more tragic. The 1955 inactivated vaccine and 1961 oral vaccine transformed this from America’s most feared childhood disease to a nearly eradicated infection, with the last U.S. case in 1979.

Read more

High‑Dose Vancomycin + S. boulardii Greatly Lowers Recurrence in Recurrent C. difficile Disease

Dr. Kumar’s Take

Recurrent C. difficile disease is tough, with high relapse rates after initial therapy. This study demonstrates that increasing vancomycin dose and pairing it with S. boulardii can dramatically reduce recurrence. It compellingly shows that dosage and timing matter. For patients at high risk of recurrence, this combination deserves attention.

Key Takeaways

• Study looked at adults with recurrent C. difficile disease (CDD).
• High‑dose vancomycin (2 g/day for 10 days) + S. boulardii (1 g/day for 28 days) vs high‑dose vancomycin + placebo.
• Recurrence rates were 16.7% in the S. boulardii group vs 50% in placebo.
• Effect significant (p = .05).
• No serious adverse events observed.

Actionable Tip

If a patient has recurrent C. difficile (≥1 previous episode), consider using high‑dose vancomycin (2 grams/day for 10 days) combined with S. boulardii 1 gram/day (divided doses) for 28 days. This strategy can drop recurrence by about two‑thirds in certain settings.

Read more

Saccharomyces boulardii Reduces Recurrence of C. difficile in Recurrent Disease

Dr. Kumar’s Take

For patients who have already had C. difficile disease (CDD), recurrence is a serious risk and often harder to treat than the initial episode. This study shows that pairing S. boulardii with standard antibiotics cuts that recurrence risk substantially.

Key Takeaways

• Adults with active C. difficile disease were randomized to standard antibiotic therapy plus S. boulardii (1 g/day) or placebo for 4 weeks.
• They were followed for another 4 weeks after treatment to monitor recurrence.
• Overall recurrence rate of CDD was lower with S. boulardii plus antibiotics versus antibiotics + placebo: 26.3% vs 44.8%.
• In the subset with previous CDD episodes, recurrence was 34.6% with S. boulardii vs 64.7% with placebo.
• No significant benefit was detected in patients with first episode of CDD.
• The therapy was well tolerated with no serious adverse events linked to the probiotic.

Actionable Tip

In patients with recurrent C. difficile disease, when prescribing vancomycin or metronidazole, consider adding S. boulardii at 1 g daily for a 4‑week course, and monitor for another 4 weeks afterward to watch for recurrence.

Read more

Saccharomyces boulardii Reduces Side‑Effects in H. pylori Triple Therapy

Dr. Kumar’s Take

Eradicating H. pylori is a massive antibiotic assault on the microbiome. This study showed that while adding Saccharomyces boulardii to standard Helicobacter pylori triple therapy may not reliably increase eradication, it does meaningfully reduce side effects—diarrhea, epigastric discomfort, dyspepsia. For many patients, tolerability is the difference between completing therapy and dropping out, so this kind of benefit matters in practice.

Key Takeaways

• Adult patients (mean age ~48 years) with confirmed H. pylori infection were treated with standard 14‑day triple therapy plus either S. boulardii or placebo.
• Eradication rate was modestly higher in the S. boulardii group (71%) vs placebo (59.7%) but this difference was not statistically significant.
• Diarrhoea incidence: 14.5% in the S. boulardii group vs 30.6% in placebo.
• Epigastric discomfort (dyspeptic symptoms) were significantly less frequent in the S. boulardii group.
• Tolerability was better with S. boulardii; fewer patients reported gastrointestinal side‑effects.

Actionable Tip

When prescribing the standard 14‑day triple therapy for H. pylori (e.g., amoxicillin + clarithromycin + PPI), adding S. boulardii may help reduce side effects such as diarrhea and epigastric discomfort. Use probiotic starting with the antibiotic course, maintain for the full therapy duration, and counsel the patient that eradication improvement is possible but not guaranteed.

Read more